Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...

Following the earnings announcement, Quest Diagnostics (NYSE:DGX)' stock price rose by 0.48% in pre-market trading. The stock ...